The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to SeaStar Medical Holding Corporation’s Selective Cytopheretic Device (SCD). The device is used to treat chronic systemic inflammation in patients with end-stage renal disease (ESRD) who require chronic hemodialysis. More than 480,000 people with ESRD are treated with in-center hemodialysis at least three times a week in the US. According to Kevin Chung, MD, chief medical officer of SeaStar Medical, patients with ESRD face chronic fatigue, malnutrition, repeat hospitalizations, and a 42% five-year survival; systemic inflammation is a driver of those outcomes. ...
Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Latest News
Effects of SGLT2 inhibitors on renal outcomes in patients with CKD, heart failure, and type 2 diabetes were examined.
Baxter International has resumed all peritoneal dialysis solutions manufacturing lines at its hurricane-damaged NC facility.
Development of a transplant morbidity gene panel highlights how genetic testing could open the door to personalized care.
Researchers studied outcomes of transplant recipients who received kidneys from toxoplasma-positive versus negative donors.
A study evaluated kidney outcomes of ARNI therapy versus ACEI/ARB for TMA related to malignant hypertension.
A study documented findings on vitamin D and metabolic bone disease in children requiring prolonged CKRT.
The European label for Ozempic will be updated to include risk reduction for events related to kidney disease.
A study examined whether COVID-19 independently affects the subsequent trajectory of kidney function in patients with IgAN.
A study analyzed the fecal microbiome of patients with IgA nephropathy, focusing on their immune response to microbiota.
The NCQA awarded Interwell Health a Population Health Program Accreditation for its Interwell 360 program for those with CKD.
Advertisement
Expert Interviews
In Print
ASN Kidney Week 2024, the future of nephrology, the relationship between CKD and osteoarthritis, and more.
Tribute to Nicoloas Madias, amino acid infusion to reduce AKI risk, felzartamab results, and more.
Conferences
The American Society of Nephrology's annual meeting to highlight the latest scientific and medical advances in the field
ATC provides a forum for exchange of new scientific and clinical information relevant to transplantation.
The annual nephrology meeting organized by the European Renal Association
The National Kidney Foundation's premier educational event designed for the interprofessional kidney health team
Podcasts
The Filtrate rerecorded their episode on the PRAECIS trial regarding a blood test for preeclampsia due to listener feedback.
We had a great NephJC get together. We recorded the whole event and packaged it into a podcast.
Amino acid infusions to prevent AKI? It couldn’t be that simple, could it?
Listen to the second part of the discussion of Chapter 15 of Dr. Burton Rose's book, focused on diuretics.
Expert Columns
It is important to understand the challenges Medicare Advantage plans present for ESRD care.
Dr. Ajay Singh discusses the reasons why medical students and residents are not choosing to pursue careers in nephrology.
Critical Financial Shifts Ahead: How CY 2025 ESRD PPS Changes Could Impact Small Dialysis Facilities
Sarah Tolson reviews the key financial implications of the CMS proposed rule for the ESRD Prospective Payment System.
Ajay Singh pays tribute to the late nephrologist and researcher Nicolaos Madias, MD, of Tufts Medical Center.
The four-pillar approach to treating diabetic kidney disease (DKD) has been endorsed by high-quality trials, such as FLOW.
It is essential for nephrology practices and dialysis centers to have backup methods for processing claims.
Knowledge Hubs
Advertisement
Advertisement
Nephrology Times Chair
Ajay K. Singh, MBBS, FRCP, MBASenior Nephrologist, Brigham and Women’s Hospital | Senior Associate Dean, Harvard Medical School
Editorial Board
Mohamed G. Atta, MD, MPHProfessor of Medicine, Johns Hopkins School of Medicine
Timothy E. Bunchman, MDProfessor and Director, Pediatric Nephrology, Transplantation, and Rheumatology, Children’s Hospital of Richmond at VCU
Suphamai Bunnapradist, MD, MSProfessor of Medicine, David Geffen School of Medicine at UCLA | Research Director, Kidney Transplant Program, UCLA
Fernando C. Fervenza, MD, PhDProfessor of Medicine, Division of Nephrology and Hypertension, Mayo Clinic
Kenneth A. Liss, DOPartner, Hypertension and Nephrology Association, Eatontown, NJ
Joel M. Topf, MD, FACPAssistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.